FOLLICULAR HELPER T-CELL LYMPHOMA, ANGIOIMMUNOBLASTIC-TYPE
Clinical trials for FOLLICULAR HELPER T-CELL LYMPHOMA, ANGIOIMMUNOBLASTIC-TYPE explained in plain language.
Never miss a new study
Get alerted when new FOLLICULAR HELPER T-CELL LYMPHOMA, ANGIOIMMUNOBLASTIC-TYPE trials appear
Sign up with your email to follow new studies for FOLLICULAR HELPER T-CELL LYMPHOMA, ANGIOIMMUNOBLASTIC-TYPE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a stem cell boost keep T-Cell lymphoma away longer?
Disease control Recruiting nowThis study looks at whether giving high-dose chemotherapy followed by a transplant of the patient's own stem cells can help people with peripheral T-cell lymphoma stay in remission longer than just watching and waiting. About 294 adults aged 18 to 75 who are in their first comple…
Matched conditions: FOLLICULAR HELPER T-CELL LYMPHOMA, ANGIOIMMUNOBLASTIC-TYPE
Phase: PHASE3 • Sponsor: Eastern Cooperative Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental combo targets rare lymphoma in early trial
Disease control Recruiting nowThis phase 1 trial is testing whether adding the drug ruxolitinib to standard CHOP chemotherapy is safe and effective for people with untreated nodal T-follicular helper (TFH) cell lymphoma, a rare type of non-Hodgkin lymphoma. About 20 adults will receive the combination to find…
Matched conditions: FOLLICULAR HELPER T-CELL LYMPHOMA, ANGIOIMMUNOBLASTIC-TYPE
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC